למיקטל טבליות מסיסות/לעיסות 50 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

LAMOTRIGINE 50 MG

Commercializzato da:

GLAXO SMITH KLINE (ISRAEL) LTD

Codice ATC:

N03AX09

Forma farmaceutica:

DISPERSIBLE/CHEWABLE TABLETS

Via di somministrazione:

PER OS

Prodotto da:

GLAXO WELLCOME OPERATIONS LTD, UK

Gruppo terapeutico:

LAMOTRIGINE

Indicazioni terapeutiche:

Epilepsy: Monotherapy in adults and children over 12 years of age: 1. Simple partial seizures. 2. complex partial seizures. 3. generalised tonic clonic secondarily seizures. 4. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: 1. Simple partial seizures. 2. Complex partial seizures. 3. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

Data dell'autorizzazione:

2008-11-01